On a corporate action affecting ordinary shares of Graphite Bio, Inc. (GRPH)

On November 14, 2023, Graphite Bio, Inc. signed a merger agreement with Lenz Therapeutics, Inc. under which Graphite Bio, Inc. will acquire Lenz Therapeutics, Inc. After completion of the merger, Graphite Bio, Inc. will be renamed “LENZ Therapeutics, Inc.” and it is expected that the common stock of the combined company will trade on The Nasdaq Stock Market LLC under the symbol “LENZ”. The merger is anticipated to close in the first quarter of 2024. For more details, please, refer to the company’s website.

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.